RecruitingNCT07590973

Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism


Sponsor

Blinklab Limited

Enrollment

1,000 participants

Start Date

Feb 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study aims to evaluate how patterns of behavioral and sensorimotor responses measured using the BlinkLab Dx1 smartphone application relate to autism diagnoses in children ages 2 to 11. BlinkLab Dx1 is a non-invasive, smartphone-based application under development as a diagnostic aid for healthcare providers assessing autism. In this study, children who have undergone a neurodevelopmental assessment within the past 12 months will complete two short, video-based sessions using the BlinkLab Dx1 app. The app presents visual and auditory stimuli and records reflexive sensorimotor responses and patterns of repetitive behavior. Additionally, primary caregivers will answer a short questionnaire in the app about symptoms and development. Information about prior neurodevelopmental assessments, including documented DSM-5-based diagnoses from routine clinical practice, will be collected retrospectively. The study will examine how the app's neurobehavioral measurements relate to previously assigned clinical diagnoses. These paired data will be used to develop and evaluate a machine learning-based algorithm using separate training and testing datasets to assess whether patterns measured by BlinkLab Dx1 can help distinguish children with autism from children without an autism diagnosis. This study does not involve any treatment or medical intervention.


Eligibility

Min Age: 2 YearsMax Age: 11 Years

Inclusion Criteria5

  • Age: Children between 2 to 11 years old
  • Parent/Caregiver/Healthcare Provider Concern: The child has received a diagnostic outcome of a neurodevelopmental assessment based on DSM-5 criteria within the past 12 months.
  • Language Proficiency: Parents and subjects must have functional English capability in the home environment.
  • Informed Consent: Parents must be able to read, understand, and voluntarily sign the Informed Consent Form (ICF).
  • Videotaping: subjects must be willing to be videotaped during the diagnostic assessment by the BlinkLab App.

Exclusion Criteria4

  • Device Compatibility: Parents without smartphone capabilities necessary for using the BlinkLab app.
  • Previous Enrollment: Subjects who have been previously enrolled in any BlinkLab clinical study.
  • Location of at home testing: Not being able to complete all remote at-home study sessions within the US.
  • History of audiogenic seizures: Participants with a known history of seizures that are triggered by auditory stimuli, including reflex or startle epilepsy provoked by sounds (audiogenic seizures), or any other form of sound-induced epilepsy.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBlinkLab Dx1

BlinkLab Dx1 is a machine learning-based algorithm that generates a continuous score reflecting likelihood of autism from neurobehavioral responses (including measures such as pre-pulse inhibition and habituation, motor activity, and vocalizations) recorded during standardized video-watching sessions in a mobile application. Pre-specified thresholds, determined during model development and fixed prior to evaluation in the independent test dataset, are applied to categorize results as " Positive for autism", "Intermediate" or "Nagative for autism". Results in the intermediate category are considered indeterminate and are excluded from primary diagnostic performance analyses, which are based on participants with definitive positive or negative test results.

BEHAVIORALRetrospective Neurodevelopmental Diagnostic Assessment

The clinical reference standard is a retrospective neurodevelopmental diagnostic assessment conducted within 12 months prior to enrollment, based on DSM-5 criteria. Participants are classified as having or not having an autism diagnosis based on the documented diagnostic conclusions of these assessments.


Locations(1)

Remote study conducted nationwide; all participation occurs via smartphone app at home.

Princeton, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07590973


Related Trials